Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over ...

After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the ...

The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared ...

Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...

Shares in Novo Nordisk fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema ...

Separately, Novo Nordisk presented early data for its oral amycretin program. In Phase I and Ib/IIa trials, amycretin ...

Additionally, a supportive secondary analysis showed that 50.7% of participants with obesity treated with CagriSema reached non-obesity levels (BMI 30 kg/m²) by the end of treatment, down from a mean ...

Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing ...

Patients who took a lower dose lost more weight on average. Read more at straitstimes.com. Read more at straitstimes.com.

Novo Nordisk’s new weight-loss drug helped patients lose even more weight on average than its current Wegovy blockbuster ...

The Financial Times, reported but not verified by Reuters, covers British Airways and Singapore Airlines canceling flights to ...

Once-weekly medication results in weight loss of up to 22.7% in adults without diabetes and 15.7% in those with type 2 diabetes CHICAGO, Ju ...